DePuy Synthes, a medical device company owned by Johnson & Johnson, has expanded its range of 3D printed interbody implants for treating degenerative spine disease with the release of the CONDUIT Interbody Platform with EIT Cellular Titanium Technology.
The new platform, announced at the 34th Annual North American Spine Society (NASS) meeting, consists of 3D printed titanium interbody implants that are made to mimic the structure of natural bone to promote spinal fusion in the patient.
In the spinal fusion procedure, a collapsed disc is removed from the patient’s spine and replaced with an interbody spacer and a bone graft. The combination of these two elements helps to restore the natural length of the spine and improve alignment between the two vertebrae. The idea, as DePuy Synthes explains, is to “replace the former mobile disc space between two vertebrae with an interbody spacer so that the segment fuses as a single, solid bone.”
In recent years, additive manufacturing has helped to advanced the spinal fusion process through the creation of implants that are more like natural bone in terms of density and porosity. In the case of the CONDUIT interbody implants, for instance, the structure of the implant is 80% porous and mimics the properties of bone.
The porosity and structure of the 3D printed implant also assists in intra and post-operative visualization and closely matches the modulus of elasticity of natural bone. In general, the 3D printed porous implants are designed to facilitate and promote the growth of natural bone for bone fusion to occur.
“My experience with CONDUIT has been in both the lumbar and cervical spine,” commented Dr. Wilson Z. Ray, Neurological Surgeon at St. Louis, Missouri. “The implant allows for superior visualization, virtually no scatter on CT scan and early fusion assessment as compared to other titanium interbody devices.”
“Our goal as a spine business is to focus on the areas with the most potential to solve unmet clinical needs, and we are excited to add advanced materials to our interbody portfolio as another option for surgeons,” added Nadav Tomer, Worldwide President, Spine, DePuy Synthes. “The launch of the CONDUIT portfolio, together with our comprehensive interbody implant offerings for degenerative disc disease, helps us deliver life-enhancing spine solutions that advance the standard of care for patients everywhere.”
The CONDUIT Implants portfolio launch follows Johnson & Johnson Medical Devices Companies’ acquisition of Germany-based Emerging Implant Technologies (EIT) in 2018. The CONDUIT Implants also join the recently launched ACIS ProTi 360°
DePuy Synthes will be showcasing its CONDUIT Platform and PROTI 360° Family at NASS to show cutting-edge treatment solutions for degenerative disc disease and cervical procedures.